Vaccines
created Here
created Here
TO HELP PROTECT
THEM THERE
THEM THERE
Before you know our vax,
get to know us
get to know us
We focus solely on developing life-saving vaccines to fight infectious diseases. Novavax is here to make a difference. We never rest in our quest to protect the health of people everywhere.
Novavax was instrumental in the fight against the COVID-19 pandemic across the globe
Authorized for use in more
than 40 countries
~100 million doses delivered
around the world
Accurate as of October 2023
evolves…
We continue to expand our innovation and are working on investigational vaccines in the following areas:
COVID-19
Flu
Flu and Covid‑19 combination
Why protein-based TECHNOLOGY?
Tried and true technology
Our vaccine is built on protein subunit vaccine technology, a well-known and established platform for creating effective vaccines, used for diseases such as seasonal flu, human papillomavirus infection, and hepatitis B.
Spike protein
Coronaviruses use a protein on their surfaces, known as the spike protein, to attach themselves to human cells and cause infection. Our vaccine contains proteins that mimic the virus’ spike protein.
Nanoparticle
For our vaccine, we organize spike proteins into a nanoparticle to help the immune system learn and recognize the target spike protein on the surface of the COVID-19 virus.
Spike protein
Coronaviruses use a protein on their surfaces, known as the spike protein, to attach themselves to human cells and cause infection. Our vaccine contains proteins that mimic the virus’ spike protein.
Nanoparticle
For our vaccine, we organize spike proteins into a nanoparticle to help the immune system learn and recognize the target spike protein on the surface of the COVID-19 virus.
Our unique Matrix-M adjuvant is a key element of our protective technology
The Matrix-M adjuvant may bolster your body’s immune response when you receive a Novavax vaccine. When mixed with our vaccine protein nanoparticles, this combination of ingredients has been shown to enhance the immune system response to our vaccines.
Our Matrix-M adjuvant is derived from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (soapbark) tree.
Once all the processing steps are complete, the Matrix-M adjuvant is mixed with vaccine nanoparticles to produce the finished, ready-to-use vaccine.
Where does Matrix-M come from?
Over 10 years of
vaccine development and innovation
vaccine development and innovation
SARS
MERS
RSV
We are working to develop vaccines that will be practical as well as safe and effective
Convenient Storage
We’re developing vaccines with a focus on ease of storage and transportation
Improved Durability of Immune Response
Our nanoparticle technology, in combination with the Matrix-M adjuvant, helps promote a robust and more durable immune response
Efficient adaptability
Our proprietary approach allows us to engineer the vaccine antigen to update the vaccine as new variants emerge